APO Research
Talk to an analyst

APO RESEARCH · REPORT

Adalimumab

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Adalimumab Market Analysis and Forecast 2026-2032

22 December 2025193 pages

Choose your research edition.

Industry ResearchAdalimumab Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Adalimumab Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Adalimumab Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Adalimumab Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Adalimumab Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Adalimumab market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Adalimumab is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Adalimumab is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Adalimumab is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Adalimumab is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Adalimumab include Aark Pharmaceuticals, Amgevita, Biogen, Boehringer Ingelheim, Delphis Pharma, AbbVie, Amgen, Mylan and Sandoz, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Adalimumab, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Adalimumab, also provides the sales of main regions and countries. Of the upcoming market potential for Adalimumab, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Adalimumab sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Adalimumab market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Adalimumab sales, projected growth trends, production technology, application and end-user industry.

Adalimumab Segment by Company

Aark Pharmaceuticals

Amgevita

Biogen

Boehringer Ingelheim

Delphis Pharma

AbbVie

Amgen

Mylan

Sandoz

Adalimumab Segment by Type

Adalimumab

Adalimumab Biosimilar

Adalimumab Segment by Application

Adults

Children

Adalimumab Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Adalimumab market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Adalimumab and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Adalimumab.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Adalimumab in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Adalimumab manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Adalimumab sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Adalimumab Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Adalimumab Major Manufacturers Table 3. Adalimumab Biosimilar Major Manufacturers Table 4. Global Adalimumab Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Adults Major Manufacturers Table 6. Children Major Manufacturers Table 7. Adalimumab Industry Trends Table 8. Adalimumab Industry Drivers Table 9. Adalimumab Industry Opportunities and Challenges Table 10. Adalimumab Industry Restraints Table 11. Global Adalimumab Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 12. Global Adalimumab Revenue by Region (2021-2026) & (US$ Million) Table 13. Global Adalimumab Revenue by Region (2027-2032) & (US$ Million) Table 14. Global Adalimumab Revenue Market Share by Region (2021-2026) Table 15. Global Adalimumab Revenue Market Share by Region (2027-2032) Table 16. Global Adalimumab Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 17. Global Adalimumab Sales by Region (2021-2026) & (k units) Table 18. Global Adalimumab Sales by Region (2027-2032) & (k units) Table 19. Global Adalimumab Sales Market Share by Region (2021-2026) Table 20. Global Adalimumab Sales Market Share by Region (2027-2032) Table 21. Global Adalimumab Revenue by Manufacturers (US$ Million) & (2021-2026) Table 22. Global Adalimumab Revenue Market Share by Manufacturers (2021-2026) Table 23. Global Adalimumab Sales by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Adalimumab Sales Market Share by Manufacturers (2021-2026) Table 25. Global Adalimumab Sales Price (US$/unit) of Manufacturers (2021-2026) Table 26. Global Adalimumab Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 27. Global Adalimumab Key Manufacturers Manufacturing Sites & Headquarters Table 28. Global Adalimumab Manufacturers, Product Type & Application Table 29. Global Adalimumab Manufacturers' Establishment Date Table 30. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 31. Global Adalimumab by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 32. Global Adalimumab Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Adalimumab Revenue by Type (2021-2026) & (US$ Million) Table 34. Global Adalimumab Revenue by Type (2027-2032) & (US$ Million) Table 35. Global Adalimumab Revenue Market Share by Type (2021-2026) Table 36. Global Adalimumab Revenue Market Share by Type (2027-2032) Table 37. Global Adalimumab Sales by Type 2021 VS 2025 VS 2032 (k units) Table 38. Global Adalimumab Sales by Type (2021-2026) & (k units) Table 39. Global Adalimumab Sales by Type (2027-2032) & (k units) Table 40. Global Adalimumab Sales Market Share by Type (2021-2026) Table 41. Global Adalimumab Sales Market Share by Type (2027-2032) Table 42. Global Adalimumab Price by Type (2021-2026) & (US$/unit) Table 43. Global Adalimumab Price by Type (2027-2032) & (US$/unit) Table 44. Global Adalimumab Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 45. Global Adalimumab Revenue by Application (2021-2026) & (US$ Million) Table 46. Global Adalimumab Revenue by Application (2027-2032) & (US$ Million) Table 47. Global Adalimumab Revenue Market Share by Application (2021-2026) Table 48. Global Adalimumab Revenue Market Share by Application (2027-2032) Table 49. Global Adalimumab Sales by Application 2021 VS 2025 VS 2032 (k units) Table 50. Global Adalimumab Sales by Application (2021-2026) & (k units) Table 51. Global Adalimumab Sales by Application (2027-2032) & (k units) Table 52. Global Adalimumab Sales Market Share by Application (2021-2026) Table 53. Global Adalimumab Sales Market Share by Application (2027-2032) Table 54. Global Adalimumab Price by Application (2021-2026) & (US$/unit) Table 55. Global Adalimumab Price by Application (2027-2032) & (US$/unit) Table 56. Aark Pharmaceuticals Company Information Table 57. Aark Pharmaceuticals Business Overview Table 58. Aark Pharmaceuticals Adalimumab Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 59. Aark Pharmaceuticals Adalimumab Product Portfolio Table 60. Aark Pharmaceuticals Recent Development Table 61. Amgevita Company Information Table 62. Amgevita Business Overview Table 63. Amgevita Adalimumab Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 64. Amgevita Adalimumab Product Portfolio Table 65. Amgevita Recent Development Table 66. Biogen Company Information Table 67. Biogen Business Overview Table 68. Biogen Adalimumab Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 69. Biogen Adalimumab Product Portfolio Table 70. Biogen Recent Development Table 71. Boehringer Ingelheim Company Information Table 72. Boehringer Ingelheim Business Overview Table 73. Boehringer Ingelheim Adalimumab Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. Boehringer Ingelheim Adalimumab Product Portfolio Table 75. Boehringer Ingelheim Recent Development Table 76. Delphis Pharma Company Information Table 77. Delphis Pharma Business Overview Table 78. Delphis Pharma Adalimumab Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Delphis Pharma Adalimumab Product Portfolio Table 80. Delphis Pharma Recent Development Table 81. AbbVie Company Information Table 82. AbbVie Business Overview Table 83. AbbVie Adalimumab Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. AbbVie Adalimumab Product Portfolio Table 85. AbbVie Recent Development Table 86. Amgen Company Information Table 87. Amgen Business Overview Table 88. Amgen Adalimumab Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Amgen Adalimumab Product Portfolio Table 90. Amgen Recent Development Table 91. Mylan Company Information Table 92. Mylan Business Overview Table 93. Mylan Adalimumab Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. Mylan Adalimumab Product Portfolio Table 95. Mylan Recent Development Table 96. Sandoz Company Information Table 97. Sandoz Business Overview Table 98. Sandoz Adalimumab Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. Sandoz Adalimumab Product Portfolio Table 100. Sandoz Recent Development Table 101. North America Adalimumab Revenue by Type (2021-2026) & (US$ Million) Table 102. North America Adalimumab Revenue by Type (2027-2032) & (US$ Million) Table 103. North America Adalimumab Sales by Type (2021-2026) & (k units) Table 104. North America Adalimumab Sales by Type (2027-2032) & (k units) Table 105. North America Adalimumab Sales Price by Type (2021-2026) & (US$/unit) Table 106. North America Adalimumab Sales Price by Type (2027-2032) & (US$/unit) Table 107. North America Adalimumab Revenue by Application (2021-2026) & (US$ Million) Table 108. North America Adalimumab Revenue by Application (2027-2032) & (US$ Million) Table 109. North America Adalimumab Sales by Application (2021-2026) & (k units) Table 110. North America Adalimumab Sales by Application (2027-2032) & (k units) Table 111. North America Adalimumab Sales Price by Application (2021-2026) & (US$/unit) Table 112. North America Adalimumab Sales Price by Application (2027-2032) & (US$/unit) Table 113. North America Adalimumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 114. North America Adalimumab Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 115. North America Adalimumab Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 116. North America Adalimumab Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 117. North America Adalimumab Sales by Country (2021-2026) & (k units) Table 118. North America Adalimumab Sales by Country (2027-2032) & (k units) Table 119. North America Adalimumab Sales Price by Country (2021-2026) & (US$/unit) Table 120. North America Adalimumab Sales Price by Country (2027-2032) & (US$/unit) Table 121. United States Adalimumab Revenue (2021-2032) & (US$ Million) Table 122. Canada Adalimumab Revenue (2021-2032) & (US$ Million) Table 123. Mexico Adalimumab Revenue (2021-2032) & (US$ Million) Table 124. Europe Adalimumab Revenue by Type (2021-2026) & (US$ Million) Table 125. Europe Adalimumab Revenue by Type (2027-2032) & (US$ Million) Table 126. Europe Adalimumab Sales by Type (2021-2026) & (k units) Table 127. Europe Adalimumab Sales by Type (2027-2032) & (k units) Table 128. Europe Adalimumab Sales Price by Type (2021-2026) & (US$/unit) Table 129. Europe Adalimumab Sales Price by Type (2027-2032) & (US$/unit) Table 130. Europe Adalimumab Revenue by Application (2021-2026) & (US$ Million) Table 131. Europe Adalimumab Revenue by Application (2027-2032) & (US$ Million) Table 132. Europe Adalimumab Sales by Application (2021-2026) & (k units) Table 133. Europe Adalimumab Sales by Application (2027-2032) & (k units) Table 134. Europe Adalimumab Sales Price by Application (2021-2026) & (US$/unit) Table 135. Europe Adalimumab Sales Price by Application (2027-2032) & (US$/unit) Table 136. Europe Adalimumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 137. Europe Adalimumab Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 138. Europe Adalimumab Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 139. Europe Adalimumab Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 140. Europe Adalimumab Sales by Country (2021-2026) & (k units) Table 141. Europe Adalimumab Sales by Country (2027-2032) & (k units) Table 142. Europe Adalimumab Sales Price by Country (2021-2026) & (US$/unit) Table 143. Europe Adalimumab Sales Price by Country (2027-2032) & (US$/unit) Table 144. Germany Adalimumab Revenue (2021-2032) & (US$ Million) Table 145. France Adalimumab Revenue (2021-2032) & (US$ Million) Table 146. U.K. Adalimumab Revenue (2021-2032) & (US$ Million) Table 147. Italy Adalimumab Revenue (2021-2032) & (US$ Million) Table 148. Russia Adalimumab Revenue (2021-2032) & (US$ Million) Table 149. Spain Adalimumab Revenue (2021-2032) & (US$ Million) Table 150. Netherlands Adalimumab Revenue (2021-2032) & (US$ Million) Table 151. Switzerland Adalimumab Revenue (2021-2032) & (US$ Million) Table 152. Sweden Adalimumab Revenue (2021-2032) & (US$ Million) Table 153. Poland Adalimumab Revenue (2021-2032) & (US$ Million) Table 154. China Adalimumab Revenue by Type (2021-2026) & (US$ Million) Table 155. China Adalimumab Revenue by Type (2027-2032) & (US$ Million) Table 156. China Adalimumab Sales by Type (2021-2026) & (k units) Table 157. China Adalimumab Sales by Type (2027-2032) & (k units) Table 158. China Adalimumab Sales Price by Type (2021-2026) & (US$/unit) Table 159. China Adalimumab Sales Price by Type (2027-2032) & (US$/unit) Table 160. China Adalimumab Revenue by Application (2021-2026) & (US$ Million) Table 161. China Adalimumab Revenue by Application (2027-2032) & (US$ Million) Table 162. China Adalimumab Sales by Application (2021-2026) & (k units) Table 163. China Adalimumab Sales by Application (2027-2032) & (k units) Table 164. China Adalimumab Sales Price by Application (2021-2026) & (US$/unit) Table 165. China Adalimumab Sales Price by Application (2027-2032) & (US$/unit) Table 166. Asia Adalimumab Revenue by Type (2021-2026) & (US$ Million) Table 167. Asia Adalimumab Revenue by Type (2027-2032) & (US$ Million) Table 168. Asia Adalimumab Sales by Type (2021-2026) & (k units) Table 169. Asia Adalimumab Sales by Type (2027-2032) & (k units) Table 170. Asia Adalimumab Sales Price by Type (2021-2026) & (US$/unit) Table 171. Asia Adalimumab Sales Price by Type (2027-2032) & (US$/unit) Table 172. Asia Adalimumab Revenue by Application (2021-2026) & (US$ Million) Table 173. Asia Adalimumab Revenue by Application (2027-2032) & (US$ Million) Table 174. Asia Adalimumab Sales by Application (2021-2026) & (k units) Table 175. Asia Adalimumab Sales by Application (2027-2032) & (k units) Table 176. Asia Adalimumab Sales Price by Application (2021-2026) & (US$/unit) Table 177. Asia Adalimumab Sales Price by Application (2027-2032) & (US$/unit) Table 178. Asia Adalimumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 179. Asia Adalimumab Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 180. Asia Adalimumab Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 181. Asia Adalimumab Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 182. Asia Adalimumab Sales by Country (2021-2026) & (k units) Table 183. Asia Adalimumab Sales by Country (2027-2032) & (k units) Table 184. Asia Adalimumab Sales Price by Country (2021-2026) & (US$/unit) Table 185. Asia Adalimumab Sales Price by Country (2027-2032) & (US$/unit) Table 186. Japan Adalimumab Revenue (2021-2032) & (US$ Million) Table 187. South Korea Adalimumab Revenue (2021-2032) & (US$ Million) Table 188. India Adalimumab Revenue (2021-2032) & (US$ Million) Table 189. Australia Adalimumab Revenue (2021-2032) & (US$ Million) Table 190. Taiwan Adalimumab Revenue (2021-2032) & (US$ Million) Table 191. Southeast Asia Adalimumab Revenue (2021-2032) & (US$ Million) Table 192. SAMEA Adalimumab Revenue by Type (2021-2026) & (US$ Million) Table 193. SAMEA Adalimumab Revenue by Type (2027-2032) & (US$ Million) Table 194. SAMEA Adalimumab Sales by Type (2021-2026) & (k units) Table 195. SAMEA Adalimumab Sales by Type (2027-2032) & (k units) Table 196. SAMEA Adalimumab Sales Price by Type (2021-2026) & (US$/unit) Table 197. SAMEA Adalimumab Sales Price by Type (2027-2032) & (US$/unit) Table 198. SAMEA Adalimumab Revenue by Application (2021-2026) & (US$ Million) Table 199. SAMEA Adalimumab Revenue by Application (2027-2032) & (US$ Million) Table 200. SAMEA Adalimumab Sales by Application (2021-2026) & (k units) Table 201. SAMEA Adalimumab Sales by Application (2027-2032) & (k units) Table 202. SAMEA Adalimumab Sales Price by Application (2021-2026) & (US$/unit) Table 203. SAMEA Adalimumab Sales Price by Application (2027-2032) & (US$/unit) Table 204. SAMEA Adalimumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 205. SAMEA Adalimumab Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 206. SAMEA Adalimumab Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 207. SAMEA Adalimumab Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 208. SAMEA Adalimumab Sales by Country (2021-2026) & (k units) Table 209. SAMEA Adalimumab Sales by Country (2027-2032) & (k units) Table 210. SAMEA Adalimumab Sales Price by Country (2021-2026) & (US$/unit) Table 211. SAMEA Adalimumab Sales Price by Country (2027-2032) & (US$/unit) Table 212. Brazil Adalimumab Revenue (2021-2032) & (US$ Million) Table 213. Argentina Adalimumab Revenue (2021-2032) & (US$ Million) Table 214. Chile Adalimumab Revenue (2021-2032) & (US$ Million) Table 215. Colombia Adalimumab Revenue (2021-2032) & (US$ Million) Table 216. Peru Adalimumab Revenue (2021-2032) & (US$ Million) Table 217. Saudi Arabia Adalimumab Revenue (2021-2032) & (US$ Million) Table 218. Israel Adalimumab Revenue (2021-2032) & (US$ Million) Table 219. UAE Adalimumab Revenue (2021-2032) & (US$ Million) Table 220. Turkey Adalimumab Revenue (2021-2032) & (US$ Million) Table 221. Iran Adalimumab Revenue (2021-2032) & (US$ Million) Table 222. Egypt Adalimumab Revenue (2021-2032) & (US$ Million) Table 223. Key Raw Materials Table 224. Raw Materials Key Suppliers Table 225. Adalimumab Distributors List Table 226. Adalimumab Customers List Table 227. Research Programs/Design for This Report Table 228. Authors List of This Report Table 229. Secondary Sources Table 230. Primary Sources List of Figures Figure 1. Adalimumab Image Figure 2. Global Adalimumab Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Adalimumab Market Size Share 2021 VS 2025 VS 2032 Figure 4. Adalimumab Image Figure 5. Adalimumab Biosimilar Image Figure 6. Global Adalimumab Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Adalimumab Market Size Share 2021 VS 2025 VS 2032 Figure 8. Adults Image Figure 9. Children Image Figure 10. Global Adalimumab Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Adalimumab Revenue (2021-2032) & (US$ Million) Figure 12. Global Adalimumab Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 13. Global Adalimumab Revenue Market Share by Region: 2025 Versus 2032 Figure 14. Global Adalimumab Revenue Market Share by Region (2021-2032) Figure 15. Global Adalimumab Sales (2021-2032) & (k units) Figure 16. Global Adalimumab Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 17. Global Adalimumab Sales Market Share by Region (2021-2032) Figure 18. US & Canada & Mexico Adalimumab Sales YoY (2021-2032) & (k units) Figure 19. Europe Adalimumab Sales YoY (2021-2032) & (k units) Figure 20. China Adalimumab Sales YoY (2021-2032) & (k units) Figure 21. Asia (Excluding China) Adalimumab Sales YoY (2021-2032) & (k units) Figure 22. South America, Middle East and Africa Adalimumab Sales YoY (2021-2032) & (k units) Figure 23. Global Adalimumab Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 24. Global Adalimumab Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 25. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 26. Global Adalimumab Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Adalimumab Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 28. Global Adalimumab Revenue Market Share by Type (2021-2032) Figure 29. Global Adalimumab Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 30. Global Adalimumab Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Adalimumab Sales Market Share by Type (2021-2032) Figure 32. Global Adalimumab Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global Adalimumab Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 34. Global Adalimumab Revenue Market Share by Application (2021-2032) Figure 35. Global Adalimumab Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 36. Global Adalimumab Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Adalimumab Sales Market Share by Application (2021-2032) Figure 38. North America Adalimumab Revenue Share by Type (2021-2032) Figure 39. North America Adalimumab Sales Share by Type (2021-2032) Figure 40. North America Adalimumab Revenue Share by Application (2021-2032) Figure 41. North America Adalimumab Sales Share by Application (2021-2032) Figure 42. North America Adalimumab Revenue Share by Country (2021-2032) Figure 43. North America Adalimumab Sales Share by Country (2021-2032) Figure 44. Europe Adalimumab Revenue Share by Type (2021-2032) Figure 45. Europe Adalimumab Sales Share by Type (2021-2032) Figure 46. Europe Adalimumab Revenue Share by Application (2021-2032) Figure 47. Europe Adalimumab Sales Share by Application (2021-2032) Figure 48. Europe Adalimumab Revenue Share by Country (2021-2032) Figure 49. Europe Adalimumab Sales Share by Country (2021-2032) Figure 50. China Adalimumab Revenue Share by Type (2021-2032) Figure 51. China Adalimumab Sales Share by Type (2021-2032) Figure 52. China Adalimumab Revenue Share by Application (2021-2032) Figure 53. China Adalimumab Sales Share by Application (2021-2032) Figure 54. Asia Adalimumab Revenue Share by Type (2021-2032) Figure 55. Asia Adalimumab Sales Share by Type (2021-2032) Figure 56. Asia Adalimumab Revenue Share by Application (2021-2032) Figure 57. Asia Adalimumab Sales Share by Application (2021-2032) Figure 58. Asia Adalimumab Revenue Share by Country (2021-2032) Figure 59. Asia Adalimumab Sales Share by Country (2021-2032) Figure 60. SAMEA Adalimumab Revenue Share by Type (2021-2032) Figure 61. SAMEA Adalimumab Sales Share by Type (2021-2032) Figure 62. SAMEA Adalimumab Revenue Share by Application (2021-2032) Figure 63. SAMEA Adalimumab Sales Share by Application (2021-2032) Figure 64. SAMEA Adalimumab Revenue Share by Country (2021-2032) Figure 65. SAMEA Adalimumab Sales Share by Country (2021-2032) Figure 66. Adalimumab Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Adalimumab Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Adalimumab
  • Adalimumab Biosimilar
Applications
  • Adults
  • Children
Companies covered
  • Aark Pharmaceuticals
  • Amgevita
  • Biogen
  • Boehringer Ingelheim
  • Delphis Pharma
  • AbbVie
  • Amgen
  • Mylan
  • Sandoz

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Adalimumab Market by Type
  3. 1.2.1 Global Adalimumab Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Adalimumab
  5. 1.2.3 Adalimumab Biosimilar
  6. 1.3 Adalimumab Market by Application
  7. 1.3.1 Global Adalimumab Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Adults
  9. 1.3.3 Children
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Adalimumab Market Dynamics
  1. 2.1 Adalimumab Industry Trends
  2. 2.2 Adalimumab Industry Drivers
  3. 2.3 Adalimumab Industry Opportunities and Challenges
  4. 2.4 Adalimumab Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Adalimumab Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Adalimumab Revenue by Region
  3. 3.2.1 Global Adalimumab Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Adalimumab Revenue by Region (2021-2026)
  5. 3.2.3 Global Adalimumab Revenue by Region (2027-2032)
  6. 3.2.4 Global Adalimumab Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Adalimumab Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Adalimumab Sales by Region
  9. 3.4.1 Global Adalimumab Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Adalimumab Sales by Region (2021-2026)
  11. 3.4.3 Global Adalimumab Sales by Region (2027-2032)
  12. 3.4.4 Global Adalimumab Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Adalimumab Revenue by Manufacturers
  2. 4.1.1 Global Adalimumab Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Adalimumab Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Adalimumab Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Adalimumab Sales by Manufacturers
  6. 4.2.1 Global Adalimumab Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Adalimumab Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Adalimumab Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Adalimumab Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Adalimumab Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Adalimumab Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Adalimumab Manufacturers, Product Type & Application
  13. 4.7 Global Adalimumab Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Adalimumab Market CR5 and HHI
  16. 4.8.2 2025 Adalimumab Tier 1, Tier 2, and Tier 3
5 Adalimumab Market by Type
  1. 5.1 Global Adalimumab Revenue by Type
  2. 5.1.1 Global Adalimumab Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Adalimumab Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Adalimumab Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Adalimumab Sales by Type
  6. 5.2.1 Global Adalimumab Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Adalimumab Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Adalimumab Sales Market Share by Type (2021-2032)
  9. 5.3 Global Adalimumab Price by Type
6 Adalimumab Market by Application
  1. 6.1 Global Adalimumab Revenue by Application
  2. 6.1.1 Global Adalimumab Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Adalimumab Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Adalimumab Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Adalimumab Sales by Application
  6. 6.2.1 Global Adalimumab Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Adalimumab Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Adalimumab Sales Market Share by Application (2021-2032)
  9. 6.3 Global Adalimumab Price by Application
7 Company Profiles
  1. 7.1 Aark Pharmaceuticals
  2. 7.1.1 Aark Pharmaceuticals Company Information
  3. 7.1.2 Aark Pharmaceuticals Business Overview
  4. 7.1.3 Aark Pharmaceuticals Adalimumab Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Aark Pharmaceuticals Adalimumab Product Portfolio
  6. 7.1.5 Aark Pharmaceuticals Recent Developments
  7. 7.2 Amgevita
  8. 7.2.1 Amgevita Company Information
  9. 7.2.2 Amgevita Business Overview
  10. 7.2.3 Amgevita Adalimumab Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Amgevita Adalimumab Product Portfolio
  12. 7.2.5 Amgevita Recent Developments
  13. 7.3 Biogen
  14. 7.3.1 Biogen Company Information
  15. 7.3.2 Biogen Business Overview
  16. 7.3.3 Biogen Adalimumab Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Biogen Adalimumab Product Portfolio
  18. 7.3.5 Biogen Recent Developments
  19. 7.4 Boehringer Ingelheim
  20. 7.4.1 Boehringer Ingelheim Company Information
  21. 7.4.2 Boehringer Ingelheim Business Overview
  22. 7.4.3 Boehringer Ingelheim Adalimumab Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Boehringer Ingelheim Adalimumab Product Portfolio
  24. 7.4.5 Boehringer Ingelheim Recent Developments
  25. 7.5 Delphis Pharma
  26. 7.5.1 Delphis Pharma Company Information
  27. 7.5.2 Delphis Pharma Business Overview
  28. 7.5.3 Delphis Pharma Adalimumab Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Delphis Pharma Adalimumab Product Portfolio
  30. 7.5.5 Delphis Pharma Recent Developments
  31. 7.6 AbbVie
  32. 7.6.1 AbbVie Company Information
  33. 7.6.2 AbbVie Business Overview
  34. 7.6.3 AbbVie Adalimumab Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 AbbVie Adalimumab Product Portfolio
  36. 7.6.5 AbbVie Recent Developments
  37. 7.7 Amgen
  38. 7.7.1 Amgen Company Information
  39. 7.7.2 Amgen Business Overview
  40. 7.7.3 Amgen Adalimumab Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Amgen Adalimumab Product Portfolio
  42. 7.7.5 Amgen Recent Developments
  43. 7.8 Mylan
  44. 7.8.1 Mylan Company Information
  45. 7.8.2 Mylan Business Overview
  46. 7.8.3 Mylan Adalimumab Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Mylan Adalimumab Product Portfolio
  48. 7.8.5 Mylan Recent Developments
  49. 7.9 Sandoz
  50. 7.9.1 Sandoz Company Information
  51. 7.9.2 Sandoz Business Overview
  52. 7.9.3 Sandoz Adalimumab Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Sandoz Adalimumab Product Portfolio
  54. 7.9.5 Sandoz Recent Developments
8 North America
  1. 8.1 North America Adalimumab Market Size by Type
  2. 8.1.1 North America Adalimumab Revenue by Type (2021-2032)
  3. 8.1.2 North America Adalimumab Sales by Type (2021-2032)
  4. 8.1.3 North America Adalimumab Price by Type (2021-2032)
  5. 8.2 North America Adalimumab Market Size by Application
  6. 8.2.1 North America Adalimumab Revenue by Application (2021-2032)
  7. 8.2.2 North America Adalimumab Sales by Application (2021-2032)
  8. 8.2.3 North America Adalimumab Price by Application (2021-2032)
  9. 8.3 North America Adalimumab Market Size by Country
  10. 8.3.1 North America Adalimumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Adalimumab Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Adalimumab Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Adalimumab Market Size by Type
  2. 9.1.1 Europe Adalimumab Revenue by Type (2021-2032)
  3. 9.1.2 Europe Adalimumab Sales by Type (2021-2032)
  4. 9.1.3 Europe Adalimumab Price by Type (2021-2032)
  5. 9.2 Europe Adalimumab Market Size by Application
  6. 9.2.1 Europe Adalimumab Revenue by Application (2021-2032)
  7. 9.2.2 Europe Adalimumab Sales by Application (2021-2032)
  8. 9.2.3 Europe Adalimumab Price by Application (2021-2032)
  9. 9.3 Europe Adalimumab Market Size by Country
  10. 9.3.1 Europe Adalimumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Adalimumab Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Adalimumab Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Adalimumab Market Size by Type
  2. 10.1.1 China Adalimumab Revenue by Type (2021-2032)
  3. 10.1.2 China Adalimumab Sales by Type (2021-2032)
  4. 10.1.3 China Adalimumab Price by Type (2021-2032)
  5. 10.2 China Adalimumab Market Size by Application
  6. 10.2.1 China Adalimumab Revenue by Application (2021-2032)
  7. 10.2.2 China Adalimumab Sales by Application (2021-2032)
  8. 10.2.3 China Adalimumab Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Adalimumab Market Size by Type
  2. 11.1.1 Asia Adalimumab Revenue by Type (2021-2032)
  3. 11.1.2 Asia Adalimumab Sales by Type (2021-2032)
  4. 11.1.3 Asia Adalimumab Price by Type (2021-2032)
  5. 11.2 Asia Adalimumab Market Size by Application
  6. 11.2.1 Asia Adalimumab Revenue by Application (2021-2032)
  7. 11.2.2 Asia Adalimumab Sales by Application (2021-2032)
  8. 11.2.3 Asia Adalimumab Price by Application (2021-2032)
  9. 11.3 Asia Adalimumab Market Size by Country
  10. 11.3.1 Asia Adalimumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Adalimumab Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Adalimumab Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Adalimumab Market Size by Type
  2. 12.1.1 SAMEA Adalimumab Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Adalimumab Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Adalimumab Price by Type (2021-2032)
  5. 12.2 SAMEA Adalimumab Market Size by Application
  6. 12.2.1 SAMEA Adalimumab Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Adalimumab Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Adalimumab Price by Application (2021-2032)
  9. 12.3 SAMEA Adalimumab Market Size by Country
  10. 12.3.1 SAMEA Adalimumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Adalimumab Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Adalimumab Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Adalimumab Value Chain Analysis
  2. 13.1.1 Adalimumab Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Adalimumab Production Mode & Process
  6. 13.2 Adalimumab Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Adalimumab Distributors
  9. 13.2.3 Adalimumab Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst